The Joint Replacement Devices market is anticipated to grow from US$ 24.07 billion in 2024 to US$ 34.53 billion by 2031; the market is expected to register a CAGR of 5.4% from 2025 to 2031. The joint replacement devices market growth is attributed to the demographic shifts toward an aging population, increasing prevalence of obesity-linked osteoarthritis, and rapid technological advancements in surgical precision and implant design.

Joint replacement devices are medical appliances used to surgically remove and replace damaged or infected parts of a joint. Their purpose is to restore lost joint function and relieve the pain caused by diseases, degeneration, or traumatic injuries. These devices are mainly used in the treatment of the joints that are affected by conditions such as osteoarthritis, rheumatoid arthritis, traumatic injuries, or degenerative joint disease. Deep integration of AI and robotics for precision surgery, additive manufacturing via 3D printing for hyper-customized implants, shift toward biodegradable and regenerative biomaterials are expected to be major joint replacement devices market trends in the coming years.

The joint replacement devices market in North America is segmented into the US, Canada, and Mexico. The North America joint replacement devices market is expanding owing to several factors. The US holds the largest market share, followed by Canada. The demand for joint replacement devices in the region is fueled by the rising prevalence of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and osteoporosis-largely driven by an aging population-has significantly increased the demand for joint replacement procedures.

The US has the highest number of people undergoing joint replacement surgery compared to the rest of the world due to an increase in the number of people aged 65 and older, higher rates of obesity among people with osteoarthritis, and improvements in the quality of the American healthcare delivery system. In 2024, the American Joint Replacement Registry (AJRR) reported that 4.3 million hip and knee replacement procedures had been performed in the United States from 2012 to 2023, consisting of 3.7 million total hip replacements (THRs) and total knee replacements (TKRs). Approximately 51% of these procedures were performed on people having a THR or TKR for the first time. The volume of TKRs performed by individual surgeons increased in 2023, with an average surgeon performing 65.4 TKRs per year and a 70% increase in the number of TKRs performed in outpatient surgery centers in one year. In Canada, the Canadian Institute for Health Information (CIHI) reported that more than 117,000 hip and knee replacements were performed during the 2021-2022 fiscal year, representing a 5.9% increase over the previous year. PROMs (patient-reported outcome measures) have become established as commonly used quality improvement tools in both countries. By 2023, 44% of U.S. facilities were submitting PROMs as part of the AJRR's quality improvement program.

The rising number of older adults, the large proportion of people who are obese, and the increasing number of individuals suffering from osteoarthritis are driving the growth of the joint replacement device market in the US. The majority of joint replacement market share is held by TKA and THA, with the cementless series being most recommended for younger patients, and robotic-assisted TKA is used to assist in providing enhanced precision during surgical procedures. Every year, the US performs approximately 790,000 TKRs (Total Knee Replacements) and 544,000 THRs (Total Hip Replacements). The AJRR (American Joint Replacement Registry) captured 596,278 total hip and knee replacement surgeries for 2023 alone; this number added to the previous total of 3.7 million valid cases from 2012 to 2023. Approximately 1.9 million (nearly 63%) of the total TKRs and 1.2 million (approximately 37%) of the total THRs that were recorded have been primary TKRs and primary THRs, respectively. Other trends are reflected in the progressive shift from traditional, inpatient-based medical facilities to outpatient surgery centers for a greater portion of joint replacements; between 2023, the number of TKA performed at outpatient facilities rose 70% YOY to 62,110 persons, and also the mean length of hospital stay for TKA dropped to 1.1 days. The number of robotic-assisted TKRs in the US rose to 15.9%. Also, the number of total hip replacements using cementless fixation increased to 21.8%. Revision procedures account for 9% to 10% of all THR surgeries, which can be attributed to infections and implant looseness. A total of 1,447 medical facilities (hospitals, ASCs, etc.) and 4,954 surgeons provided aggregated data on the AJRR in 2023, indicating that a comprehensive number of joint replacement device information was available to patients across every state.

The US Food and Drug Administration, World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), American Association of Hip and Knee Surgeons (AAHKS), and WHO (World Health Organization) are among the primary and secondary sources referred to while preparing the joint replacement devices market report.